

# Tianna Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6138532/publications.pdf>

Version: 2024-02-01

17  
papers

311  
citations

1163117

8  
h-index

1199594

12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

590  
citing authors

#	ARTICLE	IF	CITATIONS
1	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology</i> , The, 2018, 17, 597-608.	10.2	101
2	ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. <i>Theranostics</i> , 2020, 10, 5943-5956.	10.0	76
3	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. <i>Nature Communications</i> , 2018, 9, 5410.	12.8	30
4	Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. <i>Oncolmmunology</i> , 2021, 10, 1956142.	4.6	22
5	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. <i>European Journal of Cancer</i> , 2022, 162, 221-236.	2.8	22
6	Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. <i>Oncotarget</i> , 2018, 9, 8054-8067.	1.8	15
7	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2023, 84, 307-319.	0.8	10
8	Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1797-1808.	4.1	9
9	<sc>AZD8055</sc> enhances <i>in vivo</i> efficacy of afatinib in chordomas. <i>Journal of Pathology</i> , 2021, 255, 72-83.	4.5	9
10	&lt;p&gt;Identification of the Different Roles and Potential Mechanisms of T Isoforms in the Tumor Recurrence and Cell Cycle of Chordomas&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11777-11791.	2.0	8
11	Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model. <i>PLoS ONE</i> , 2021, 16, e0251957.	2.5	8
12	RARE-29. AZD8055 ENHANCES IN VIVO EFFICACY OF AFATINIB IN CHORDOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi227-vi227.	1.2	1
13	PDTM-06. DISULFIRAM-COPPER PROLONGS SURVIVAL AND REDUCES STEM-CELLNESS IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA THROUGH NUCLEAR SEQUESTRATION OF NPL4. <i>Neuro-Oncology</i> , 2019, 21, vi188-vi188.	1.2	0
14	CDKS Blockade Enhances In Vivo Efficacy of EGFR Inhibition in Chordomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2021, 82, .	0.8	0
15	Multicenter Study on Clinical Outcomes of Olfactory Neuroblastoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2021, 82, .	0.8	0
16	Establishment and Characterization of Two Novel Olfactory Neuroblastoma Cell Lines. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, .	0.8	0
17	EXTH-61. COMBINATION OF DISULFIRAM AND COPPER INDUCES NPL4 AGGREGATION, TARGETS CD133-NESTIN CELLS AND EXTENDS SURVIVAL IN MEDULLOBLASTOMA GROUP 3 MODELS. <i>Neuro-Oncology</i> , 2020, 22, ii100-ii100.	1.2	0